Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Mizuho analyst Graig Suvannavejh maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and lowers the price target from $100 to $98.
Mizuho analyst Graig Suvannavejh maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and lowers the price target from $100 to $98.